Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSCHSTC:DVN 81 EV-to-EBIT is 5.67 as of Aug. 22, 2026, which is 52% below its 10-year median of 11.78. GuruFocus rates HSTC:DVN with a GF Score™ of 81/100 and a GF Value™ of ₫22,202.04 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks better than 86.52% on this metric.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Viet Nam Pharmaceutical - JSC's Enterprise Value for the quarter that ended in Jun. 2026 was ₫5,452,269 Mil.
Viet Nam Pharmaceutical - JSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫874,394 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC EV-to-EBIT Related Terms
Viet Nam Pharmaceutical - JSC EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's EV-to-EBIT falls into.
Viet Nam Pharmaceutical - JSC's current Enterprise Value is ₫4,954,569 Mil.
Viet Nam Pharmaceutical - JSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫874,394 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a EV-to-EBIT of 5.67 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. This is 52% below median its historical median of 11.78. Over the past decade, Viet Nam Pharmaceutical - JSC's EV-to-EBIT has ranged from 5.64 to 26.69. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #93 out of 690 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Viet Nam Pharmaceutical - JSC's EV-to-EBIT too high?
Viet Nam Pharmaceutical - JSC's current EV-to-EBIT of 5.67 is 52% below median its 10-year median of 11.78. Over the past 10 years, this metric has ranged from a low of 5.64 to a high of 26.69. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Viet Nam Pharmaceutical - JSC's value of 5.67 is 62.5% below this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #93 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #93 out of 690 companies for EV-to-EBIT. This places Viet Nam Pharmaceutical - JSC in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.12. Viet Nam Pharmaceutical - JSC's value of 5.67 is 62.5% below this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own EV-to-EBIT has ranged from 5.64 to 26.69 over the past decade. While the company's 10-year median is 11.78 vs. the industry median of 15.12, Viet Nam Pharmaceutical - JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current EV-to-EBIT of 5.67 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current EV-to-EBIT is 5.67, which is 52% below median its own 10-year median of 11.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,202.04, compared to a current price of ₫18,100.00 — trading 18.5% below its estimated fair value. The current EV-to-EBIT is 5.67, which is 52% below median its 10-year median of 11.78 and 62.5% below the Drug Manufacturers industry median of 15.12. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current EV-to-EBIT is 5.67 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫18,100.00 is trading 18.5% below its estimated GF Value™ of ₫22,202.04.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
EV-to-EBIT: 5.67 (52% below median its 10-year median of 11.78)
GF Value™: ₫22,202.04 vs. price of ₫18,100.00 (18.5% below fair value)
Industry Position: 62.5% below the Drug Manufacturers median (#93 of 690)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
81GF Score
Get the complete analysis for HSTC:DVN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
